ArticleLa Radiologia medica2026
Image-guided adaptive interventional radiotherapy (modern brachytherapy) boost for vaginal recurrences.
Article in La Radiologia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate clinical outcomes in patients with vaginal recurrences treated with radiotherapy with or without chemotherapy, followed by image-guided interventional radiotherapy (IG-IRT).
methodsWe retrospectively analyzed patients with vaginal recurrences treated with external beam radiotherapy (EBRT) ± chemotherapy followed by endovaginal high dose rate IG-IRT. The EBRT total dose was 45 Gy. The interventional radiotherapy boost delivered 28 Gy in four high-dose-rate fractions, achieving 85-95 Gy EQD2 (α/β 10) to the high-risk clinical target volume and 60 Gy EQD2 (α/β 10) to the intermediate-risk clinical target volume. The primary endpoint was local control. Secondary endpoints included metastasis-free survival, overall survival, cancer-specific survival, and acute and late toxicities.
resultsThirty-two patients (median age, 54 years) were included. Two-year actuarial local control, metastasis-free survival, overall survival, and cancer-specific survival rates were 100%, 77.8%, 93%, and 93%, respectively. At univariate analysis, chemotherapy was significantly associated with a reduced risk of metastasis (p = 0.0038). Among chemotherapy regimens, cisplatin-based therapy showed the lowest metastatic risk, with metastases occurring in 5% of patients (p = 0.019). Age > 59 years was significantly associated with increased mortality (p = 0.026). At multivariate analysis, age was the only independent predictor of mortality (p < 0.05). Acute grade 2 gastrointestinal and skin toxicity occurred in two patients, while one patient experienced late grade 3 vaginal stenosis.
conclusionsImage-guided interventional radiotherapy as a boost following EBRT for vaginal cuff recurrences is an effective and safe treatment option, providing excellent local control with a favourable toxicity profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.